Pyxis Oncology IncQ) expected to post a loss of 35 cents a share - Earnings Preview
Pyxis Oncology IncQ) is expected to report a loss of 35 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $6.00, representing an 82.2% increase from the last closing price of $1.07. Previous earnings performance shows mixed results, with several beats and misses in the last quarters. This summary was generated on August 8, 2023.
- Pyxis Oncology Inc (PYXS.OQ) (PYXS.O) is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025
- LSEG’s mean analyst estimate for Pyxis Oncology Inc is for a loss of 35 cents per share.
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 6 “strong buy” or “buy,” 1 “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts was unchanged in the last three months.
- Wall Street’s median 12-month price target for Pyxis Oncology Inc is $6.00, about 82.2% above its last closing price of $1.07 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -0.29 -0.29 -0.35 Missed -19
Dec. 31 2025 -0.34 -0.33 -0.25 Beat 24.2
Sep. 30 2024 -0.31 -0.31 -0.35 Missed -11.7
Jun. 30 2024 -0.32 -0.32 -0.29 Beat 10.6
Mar. -0.21 -0.24 -0.06 Beat 75.2
31 2024
Dec. 31 2023 -0.48 -0.47 -0.33 Beat 30.5
Sep. 30 2023 -0.49 -0.51 -0.56 Missed -10.5
Jun. 30 2023 -0.64 -0.65 -0.41 Beat 36.7
This summary was machine generated August 8 at 11:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
